EXOZ
EXOZYMES INC.
NASDAQ · Healthcare · Biotechnology · US
$6.44
+3.96%Sep 8, 2026, 14:20 UTC
eXoZymes Inc. announced an agreement with Curia Global, Inc. to initiate commercial-scale manufacturing of its NCT product, with the program expected to commence in Q4 2026 and a roadmap for larger-scale production in 2027.
Source:Aug 18, 2026, 20:30 UTC
eXoZymes announced that its optimized NCT process achieved a 10-fold productivity increase, advancing beyond original commercial-scale economic targets.
Jul 23, 2026, 20:15 UTC
eXoZymes was selected by the U.S. Department of Energy for the Genesis Mission to collaborate with Lawrence Berkeley National Laboratory on AI-powered digital twins for cell-free biomanufacturing, with total funding of approximately $747,000 including $147,000 awarded to eXoZymes.
Source:Jun 17, 2026, 20:10 UTC
eXoZymes Inc. closed an underwritten public offering of common stock and warrants, raising approximately $5.95 million in gross proceeds.
Source:Jun 8, 2026, 00:00 UTC
eXoZymes Inc. agreed to issue and sell 296,135 units (each containing 2 shares of common stock and 1 warrant) to MDB Capital in a firm commitment underwritten offering expected to close on June 9, 2026.
Source: